Mozart Therapeutics

Seattle, United States Founded: 2020 • Age: 6 yrs
Therapeutics for autoimmune and inflammatory diseases are developed.

About Mozart Therapeutics

Mozart Therapeutics is a company based in Seattle (United States) founded in 2020.. Mozart Therapeutics has raised $80 million across 2 funding rounds from investors including AbbVie, Lilly and Pfizer. The company has 14 employees as of December 31, 2021. Mozart Therapeutics offers products and services including MTX-101 and MTX-201. Mozart Therapeutics operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.

  • Headquarter Seattle, United States
  • Employees 14 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Mozart Therapeutics, Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $80 M (USD)

    in 2 rounds

  • Latest Funding Round
    $25 M (USD), Series A

    Jun 07, 2023

  • Investors
    AbbVie

    & 11 more

  • Employee Count
    14

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Mozart Therapeutics

Mozart Therapeutics offers a comprehensive portfolio of products and services, including MTX-101 and MTX-201. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Modulates CD8 Treg cells to restore immune balance in autoimmune diseases.

Targets CD8 Treg dysfunction for treating inflammatory disorders.

People of Mozart Therapeutics
Headcount 1-10
Employee Profiles 12
Board Members and Advisors 13
Employee Profiles
People
Monica Anderson Childs
Sr Scientist
People
Katie Fanning
President & CEO
People
Kristine Swiderek
Chief Scientific Officer
People
Russ Hawkinson
Chief Financial Officer

Unlock access to complete

Board Members and Advisors
people
Gerald T. Nepom
Advisor
people
Jasmina Marjanovic
Director
people
Marie-Claire Peakman
Director
people
Henrijette Richter
Director

Unlock access to complete

Funding Insights of Mozart Therapeutics

Mozart Therapeutics has successfully raised a total of $80M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $25.0M
  • First Round

    (26 Oct 2021)

  • Investors Count 12
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2023 Amount Series A - Mozart Therapeutics Valuation

investors

Oct, 2021 Amount Series A - Mozart Therapeutics Valuation Arch Venture Partners , Sofinnova Partners
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Mozart Therapeutics

Mozart Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Lilly and Pfizer. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Sofinnova Partners is focused on life sciences and healthcare investments.
Founded Year Domain Location
Venture capital firm focused on life science companies
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Mozart Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Mozart Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Mozart Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Mozart Therapeutics

Mozart Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Plasma-based biologics are developed for immune deficiency and infectious diseases.
domain founded_year HQ Location
Small molecule protein degraders are developed for various disorders.
domain founded_year HQ Location
Immunotherapeutics for cancer and other diseases are developed.
domain founded_year HQ Location
Developer of novel protein-based therapeutics using machine learning and biological engineering
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Mozart Therapeutics

When was Mozart Therapeutics founded?

Mozart Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Mozart Therapeutics located?

Mozart Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Who is the current CEO of Mozart Therapeutics?

Katie Fanning is the current CEO of Mozart Therapeutics.

Is Mozart Therapeutics a funded company?

Mozart Therapeutics is a funded company, having raised a total of $80M across 2 funding rounds to date. The company's 1st funding round was a Series A of $55M, raised on Oct 26, 2021.

How many employees does Mozart Therapeutics have?

As of Dec 31, 2021, the latest employee count at Mozart Therapeutics is 14.

What does Mozart Therapeutics do?

Mozart Therapeutics was founded in 2020 and is based in Seattle, United States. Biologics targeting a network of pathogenic CD4 and cytolytic-regulatory CD8 T cells are developed for treating immunological disorders. The focus is placed on immune modulators within the biotechnology sector to address autoimmune and inflammatory conditions through therapeutic solutions.

Who are the top competitors of Mozart Therapeutics?

Mozart Therapeutics's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.

What products or services does Mozart Therapeutics offer?

Mozart Therapeutics offers MTX-101 and MTX-201.

Who are Mozart Therapeutics's investors?

Mozart Therapeutics has 12 investors. Key investors include AbbVie, Lilly, Pfizer, Bayer, and ARE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available